← Back to Screener
Glaukos Corporation (GKOS)
Price$103.12
Value ScoreF
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-7.37%
Price vs S&P 500 (4W)-31.27%
VGM Score45.96
Market Capitalization$6.09B
All Metrics
Book Value / Share (Quarterly)$11.50
P/TBV (Annual)12.61x
Revenue Growth (3Y)21.50%
Cash Flow / Share (Quarterly)$-0.60
Price vs S&P 500 (YTD)-19.40%
Gross Margin (TTM)78.08%
Net Profit Margin (TTM)-34.34%
EPS (TTM)$-3.29
10-Day Avg Trading Volume1.47M
EPS Excl Extra (TTM)$-3.29
Revenue Growth (5Y)17.66%
EPS (Annual)$-3.28
ROI (Annual)-25.87%
Gross Margin (Annual)77.97%
Net Profit Margin (5Y Avg)-33.98%
Cash / Share (Quarterly)$4.74
Revenue Growth QoQ (YoY)41.16%
ROA (Last FY)-21.01%
Revenue Growth TTM (YoY)36.30%
EBITD / Share (TTM)$-3.19
ROE (5Y Avg)-20.80%
Operating Margin (TTM)-36.05%
Cash Flow / Share (Annual)$-0.68
P/B Ratio9.08x
P/B Ratio (Quarterly)9.32x
Net Income / Employee (Annual)$-171,600
EV / Revenue (TTM)10.99x
Net Interest Coverage (TTM)-28.92x
ROA (TTM)-20.07%
EV / EBITDA (TTM)1898.88x
EPS Incl Extra (Annual)$-3.28
Current Ratio (Annual)4.69x
Quick Ratio (Quarterly)4.43x
3-Month Avg Trading Volume0.84M
52-Week Price Return8.94%
Revenue / Employee (TTM)$504,000
Tangible BV / Share (Quarterly)$9.22
P/S Ratio (Annual)12.01x
Asset Turnover (Annual)0.57x
52-Week High$148.11
Operating Margin (5Y Avg)-30.48%
EPS Excl Extra (Annual)$-3.28
CapEx CAGR (5Y)28.46%
Tangible BV CAGR (5Y)10.67%
26-Week Price Return8.56%
Quick Ratio (Annual)3.82x
13-Week Price Return-14.89%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)5.43x
Enterprise Value$6.06B
Revenue / Share Growth (5Y)11.90%
Asset Turnover (TTM)0.58x
Book Value / Share Growth (5Y)-5.03%
Revenue / Employee (Annual)$463,800
Inventory Turnover (Annual)1.84x
Pretax Margin (Annual)-38.04%
Cash / Share (Annual)$4.85
3-Month Return Std Dev65.19%
Gross Margin (5Y Avg)76.48%
Net Income / Employee (TTM)$-173,100
ROE (Last FY)-28.60%
Net Interest Coverage (Annual)-74.14x
EPS Basic Excl Extra (Annual)$-3.28
P/FCF (TTM)1551.01x
Receivables Turnover (TTM)5.77x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$-3.29
Receivables Turnover (Annual)5.99x
ROI (TTM)-24.16%
P/S Ratio (TTM)11.05x
Pretax Margin (5Y Avg)-34.01%
Revenue / Share (Annual)$8.87
Tangible BV / Share (Annual)$8.94
Price vs S&P 500 (52W)-19.27%
Year-to-Date Return-8.47%
5-Day Price Return-14.04%
EPS Normalized (Annual)$-3.28
ROA (5Y Avg)-13.00%
Net Profit Margin (Annual)-36.99%
Month-to-Date Return-28.06%
Cash Flow / Share (TTM)$-1.99
EBITD / Share (Annual)$-3.44
Operating Margin (Annual)-39.33%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-15.28%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.29
P/TBV (Quarterly)11.62x
P/B Ratio (Annual)9.88x
Inventory Turnover (TTM)1.98x
Pretax Margin (TTM)-35.28%
Book Value / Share (Annual)$11.41
Price vs S&P 500 (13W)-24.64%
Beta0.80x
P/FCF (Annual)713.58x
Revenue / Share (TTM)$9.50
ROE (TTM)-26.46%
52-Week Low$73.16
vGradeF
gGradeA
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.18est. -0.28
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.18
4.18
4.18
4.24
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GKOSGlaukos Corporation | F | A | C | $103.12 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
Glaukos develops innovative ophthalmic therapies and devices for treating glaucoma, corneal disorders, and retinal diseases. The company commercializes the iStent family of micro-scale glaucoma surgical devices and the novel iDose TR intracameral implant, which delivers continuous glaucoma medication directly inside the eye as an alternative to daily eye drops. It also offers treatment for keratoconus, a rare corneal condition.